Anosmia and / or Ageusia and Early Corticosteroid Use
- Conditions
- Covid19Anosmia
- Interventions
- Drug: Late dexamethazoneDrug: Early-Dexamethasone
- Registration Number
- NCT04528329
- Lead Sponsor
- ClinAmygate
- Brief Summary
Time to recover of Anosmia and / or ageusia and early corticosteroid use
- Detailed Description
In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone.
Time to recover of Anosmia and / or ageusia and early corticosteroid use
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- Any case with COVID-19
- Age more than or equal to 18 years
- Mild to moderate severity
- Diabetes
- Any contra-indication for the interventional drug
- Mentally disabled cases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Late CS Late dexamethazone Dexamethasone is to be used lately upon the deterioration of cases Early CS Early-Dexamethasone early use of dexamethasone as early as the laboratory confirmation of inflammation.
- Primary Outcome Measures
Name Time Method Time to recovery one to 6 weeks Time to recovery from anosmia and / or agusia
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Asalam
🇪🇬Maadi, Cairo, Egypt